Dr. Reddy`s Announces the Launch of Metoprolol Succinate ER (Extended-Release) Tablets

Tue Sep 11, 2012 9:39am EDT

* Reuters is not responsible for the content in this press release.

Dr. Reddy’s Announces the Launch of Metoprolol Succinate ER (Extended-Release) Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that is has launched Metoprolol Succinate ER (Extended-Release) Tablets (25 mg, 50 mg, 100 mg & 200 mg), a bioequivalent generic version of Toprol-XL® (Metoprolol Succinate) Tablets in the US market on September 10, 2012. Metoprolol ER (Extended-Release) Tablets (25 mg, 50 mg, 100 mg, & 200 mg) was approved by the United States Food & Drug Administration (USFDA) in August 2012.

The Toprol-XL® brand and generic had U.S. sales of approximately $1.13 billion for the most recent twelve months ending June 2012 according to IMS Health*.

Dr. Reddy’s Metoprolol Succinate ER tablets in 25 mg, 50 mg, 100 mg and 200 mg are available in bottle counts of 100 and 500.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: www.drreddys.com.

Toprol-XL® is a registered trademark of AstraZeneca.

*IMS National Sales Perspectives: Retail and Non-Retail MAT June 2012

Investors and Financial Analysts:
Kedar Upadhye, +91-40-66834297
kedaru@drreddys.com
or
Saunak Savla, +91-40-49002135
saunaks@drreddys.com
or
Milan Kalawadia (USA), +1 908-203-4931
mkalawadia@drreddys.com
or
Media:
S Rajan, +91-40- 49002445
rajans@drreddys.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.